554 related articles for article (PubMed ID: 12231533)
21. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
[TBL] [Abstract][Full Text] [Related]
22. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
23. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
24. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
25. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
[TBL] [Abstract][Full Text] [Related]
26. Analysis of FHIT allelic imbalance/loss of heterozygosity and FHIT expression in cutaneous squamous cell carcinomas.
Gray SE; Kay E; Leader M; Mabruk M
J Cutan Pathol; 2008 Sep; 35(9):816-25. PubMed ID: 18494825
[TBL] [Abstract][Full Text] [Related]
27. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
28. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
29. [Loss of heterozygosity on chromosome 3p in breast cancer and precancerous lesion].
Tang XL; Yao GY; Chen LR; Yang ZR; Li SL
Zhonghua Wai Ke Za Zhi; 2006 Oct; 44(19):1314-7. PubMed ID: 17217815
[TBL] [Abstract][Full Text] [Related]
30. [Allelic loss and down-regulation of FHIT gene expression in esophageal squamous cell carcinoma].
Liu FX; Huang XP; Zhao CX; Xu X; Han YL; Cai Y; Wu RL; Wu M; Zhan QM; Wang MR
Ai Zheng; 2004 Sep; 23(9):992-8. PubMed ID: 15363189
[TBL] [Abstract][Full Text] [Related]
31. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
32. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
Burke L; Khan MA; Freedman AN; Gemma A; Rusin M; Guinee DG; Bennett WP; Caporaso NE; Fleming MV; Travis WD; Colby TV; Trastek V; Pairolero PC; Tazelaar HD; Midthun DE; Liotta LA; Harris CC
Cancer Res; 1998 Jun; 58(12):2533-6. PubMed ID: 9635574
[TBL] [Abstract][Full Text] [Related]
33. FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas.
Bugert P; Wilhelm M; Kovacs G
Genes Chromosomes Cancer; 1997 Sep; 20(1):9-15. PubMed ID: 9290948
[TBL] [Abstract][Full Text] [Related]
34. Hypermethylation of the 5'CpG island of the FHIT gene in clear cell renal carcinomas.
Kvasha S; Gordiyuk V; Kondratov A; Ugryn D; Zgonnyk YM; Rynditch AV; Vozianov AF
Cancer Lett; 2008 Jul; 265(2):250-7. PubMed ID: 18378390
[TBL] [Abstract][Full Text] [Related]
35. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
36. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
Ingvarsson S; Sigbjornsdottir BI; Huiping C; Jonasson JG; Agnarsson BA
Cancer Detect Prev; 2001; 25(3):292-8. PubMed ID: 11425271
[TBL] [Abstract][Full Text] [Related]
37. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
38. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir.
Syeed N; Husain SA; Sameer AS; Chowdhri NA; Siddiqi MA
Mutat Res; 2011 Feb; 707(1-2):1-8. PubMed ID: 21095196
[TBL] [Abstract][Full Text] [Related]
39. Chromosome 3p and breast cancer.
Yang Q; Yoshimura G; Mori I; Sakurai T; Kakudo K
J Hum Genet; 2002; 47(9):453-9. PubMed ID: 12202982
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene.
Cheng CW; Wu PE; Yu JC; Huang CS; Yue CT; Wu CW; Shen CY
Oncogene; 2001 Jun; 20(29):3814-23. PubMed ID: 11439345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
